TERN vs VTR · $6.12B cap vs P/E 149, rev $4.92B
Terns Pharmaceuticals Inc (TERN) versus Ventas Inc (VTR) — a side-by-side from cached financials, not a winner call.
Terns Pharmaceuticals Inc (TERN) is a biotechnology company listed on NASDAQ.
Ventas Inc (VTR) is a reit - healthcare facilities company listed on NYSE.
Latest reported TERN revenue for 2022-12-31 was $0. Net income was -$60.3M. TERN currently screens at market cap $6.12B.
Latest reported VTR revenue for 2024-12-31 was $4.92B. Net income was $88.4M. Revenue was up 9.5% from 2023-12-31 to 2024-12-31. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
TERN currently screens at market cap $6.12B. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
Not investment advice. Open the TERN and VTR stock pages for the full models.
Not investment advice.